Krazati is owned by Mirati Theraps.
Krazati contains Adagrasib.
Krazati has a total of 1 drug patent out of which 0 drug patents have expired.
Krazati was authorised for market use on 12 December, 2022.
Krazati is available in tablet;oral dosage forms.
Krazati can be used as treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior systemic therapy.
Drug patent challenges can be filed against Krazati from 2026-12-12.
The generics of Krazati are possible to be released after 17 May, 2037.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US10689377||MIRATI THERAPS||KRas G12C inhibitors|| |
(14 years from now)
|New Chemical Entity Exclusivity (NCE)||Dec 12, 2027|
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 2026-12-12
Market Authorisation Date: 12 December, 2022
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic